Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease

Immunobiology

Volumn 215, Issue 8, 2010, Pages 611-616

  O'Sullivan, S E ^a   Kendall, D A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anti inflammatory; Cannabinoid; Endocannabinoid; Neuroinflammation; Nuclear receptor; Peroxisome proliferator activated receptor

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ACYLETHANOLOAMINE; AJULEMIC ACID; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CELL NUCLEUS RECEPTOR; DEXANABINOL; DOPAMINE DERIVATIVE; DRONABINOL; ENDOCANNABINOID; N ARACHIDONOYLDOPAMINE; N OLEOYLETHANOLAMINE; NOLADIN ETHER; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VIRODHAMINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CELL DIFFERENTIATION; CELL SURFACE; DRUG TARGETING; FEEDING; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; METABOLISM; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; ANIMAL; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; REVIEW;

ANIMALS; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; INFLAMMATION; NEUROIMMUNOMODULATION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 77954175115     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2009.09.007     Document Type: Article

References (73)

1. Alexander S.P., Kendall D.A. The complications of promiscuity: endocannabinoid action and metabolism. Br. J. Pharmacol. 2007, 152:602-623.
2. Astarita G., Di Giacomo B., Gaetani S., Oveisi F., Compton T.R., Rivara S. Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J. Pharmacol. Exp. Ther. 2006, 318:563-570.
3. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997, 46:1319-1327.
4. Barish G.D., Narkar V.A., Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 2006, 116:590-597.
5. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
6. Bernardo A., Minghetti L. Regulation of Glial Cell Functions by PPAR-gamma natural and Synthetic Agonists. PPAR Res. 2008, 2008:864140.
7. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol. 2000, 129:823-834.
8. Bishop-Bailey D., Bystrom J., 2009. Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation. Pharmacol. Ther.. [Epub ahead of print July 14 2009].
9. Bouaboula M., Hilairet S., Marchand J., Fajas L., Le Fur G., Casellas P. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol. 2005, 517:174-181.
10. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder C.C. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 2000, 396:141-149.
11. Campolongo P., Roozendaal B., Trezza V., Cuomo V., Astarita G., Fu J., McGaugh J.L., Piomelli D. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc. Natl. Acad. Sci. USA 2009, 106:8027-8031.
12. Cimini A., Benedetti E., Cristiano L., Sebastiani P., D'Amico M.A., D'Angelo B., et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 2005, 130:325-337.
13. Costa B., Comelli F., Bettoni I., Colleoni M., Giagnoni G.. 2008. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. [Epub ahead of print].
14. Cabral G.A., Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev. Mol. Med. 2009, 11:e3.
15. D'Agostino G., La Rana G., Russo R., Sasso O., Iacono A., Esposito E., Mattace Raso G., Cuzzocrea S., LoVerme J., Piomelli D., Meli R., Calignano A. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur. J. Pharmacol. 2009, 613:54-59.
16. D'Agostino G., La Rana G., Russo R., Sasso O., Iacono A., Esposito E., Raso G.M., Cuzzocrea S., LoVerme J., Piomelli D., Meli R., Calignano A. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J. Pharmacol. Exp. Ther. 2007, 322:1137-1143.
17. Delerive P., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 2001, 169:453-459.
18. Demuth D.G., Molleman A. Cannabinoid signalling. Life Sci. 2006, 78:549-563.
19. de Ubago M.M., García-Oya I., Pérez-Pérez A., Canfrán-Duque A., Quintana-Portillo R., de Fonseca F.R., González-Yanes C., Sánchez-Margalet V. Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits insulin receptor signalling in HTC rat hepatoma cells. Biochim. Biophys. Acta 2009, 1791:740-745.
20. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2005, CB2:29.
21. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53:S43-S50.
22. Fievet C., Fruchart J.C., Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr. Opin. Pharmacol. 2006, 6:606-614.
23. Fu J., Gaetani S., Oveisi F., LoVerme J., Serrano A., Rodriguez De Fonseca F. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003, 425:90-93.
24. Gasperi V., Fezza F., Pasquariello N., Bari M., Oddi S., Agro A.F. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell. Mol. Life Sci. 2007, 64:219-229.
25. Glass C.K. Going nuclear in metabolic and cardiovascular disease. J. Clin. Invest. 2006, 116:556-560.
26. Graham E.S., Ashton J.C., Glass M. Cannabinoid receptors: a brief history and "what's hot". Front. Biosci. 2009, 14:944-957.
27. Guzman M., LoVerme J., Fu J., Oveisi F., Blazquez C., Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J. Biol. Chem. 2004, 279:27849-27854.
28. Holzer P. The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor. Br. J. Pharmacol. 2008, 155:1145-1162.
29. Hwang J., Kleinhenz D.J., Lassegue B., Griendling K.K., Dikalov S., Hart C.M. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell Physiol. 2005, 288:C899-C905.
30. Jasińska M., Owczarek J., Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol. Reports 2007, 59:483-499.
31. Janke J., Schupp M., Engeli S. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation. J. Hypertension 2006, 24:1809-1816.
32. Jhaveri M.D., Richardson D., Robinson I., Garle M.J., Patel A., Sun Y., Sagar D.R., Bennett A.J., Alexander S.P., Kendall D.A., Barrett D.A., Chapman V. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferatoractivated receptor-alpha in a model of inflammatory pain. Neuropharmacology 2008, 55:85-93.
33. Kaczocha M., Glaser S.T., Deutsch D.G. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl. Acad. Sci. USA 2009, 106:6375-6380.
34. Karaliota S., Siafaka-Kapadai A., Gontinou C., Psarra K., Mavri-Vavayanni M., 2009. Anandamide Increases the Differentiation of Rat Adipocytes and Causes PPARgamma and CB1 Receptor Upregulation. Obesity [Epub ahead of print].
35. Klein T.W., Cabral G.A. Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J. Neuroimmune Pharmacol. 2006, 1:50-64.
36. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. USA 1997, 94:4318-4323.
37. Kozak K.R., Crews B.C., Morrow J.D., Wang L.H., Ma Y.H., Weinander R. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J. Biol. Chem. 2002, 277:23278-23286.
38. Kuroyanagi K., Kang M.-S., Goto T. Citrus auraptene acts as an agonist for PPARs and enhances adiponectin production and MCP-1 reduction in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2008, 366:219-225.
39. Liu J., Li H., Burstein S.H., Zurier R.B., Chen J.D. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol. Pharmacol. 2003, 63:983-992.
40. LoVerme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 2005, 67:15-19.
41. LoVerme J., Russo R., La Rana G., Fu J., Farthing J., Mattace-Raso G. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 2006, 319:1051-1061.
42. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 2006, 91:3171-3180.
43. Melis M., Pillolla G., Luchicchi A., Muntoni A.L., Yasar S., Goldberg S.R., Pistis M.J. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. Neuroscience 2008, 28(December):13985-13994.
44. Mestre L., Docagne F., Correa F., Loría F., Hernangómez M., Borrell J., Guaza C. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell Neurosci. 2009, 40:258-266.
45. Miller A.M., Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. Br. J. Pharmacol. 2008, 153(2):299-308.
46. Moreno S., Farioli-Vecchioli S., Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123:131-145.
47. Mueller E., Drori S., Aiyer A., Yie J., Sarraf P., Chen H. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J. Biol. Chem. 2002, 277:41925-44193.
48. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P.A. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann. N. Y. Acad. Sci. 2008, 1139:434-449.
49. O'Sullivan S.E., Kendall D.A., Randall M.D. Time-dependent vascular effects of endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPARgamma). PPAR Res. 2009, 2009:425289.
50. O'Sullivan S.E., Sun Y., Bennett A.J., Randall M.D., Kendall D.A. Time-dependent vascular actions of cannabidiol in the rat aorta. Eur. J. Pharmacol. 2009, 612:61-68.
51. O'Sullivan S.E., Bennett A.J., Kendall D.A., Randall M.D. Cannabinoids and peroxisome proliferator-activated receptor gamma (PPARγ). Proc. Int. Cannabinoid Res. Soc. 2006, 2006b.
52. O'Sullivan S.E., Kendall D.A., Randall M.D. Further characterization of the time-dependent vascular effects of delta9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 2006, 317:428-438.
53. O'Sullivan S.E., Tarling E.J., Bennett A.J., Kendall D.A., Randall M.D. Novel time-dependent vascular actions of delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem. Biophys. Res. Commun. 2005, 337:824-831.
54. Randall M.D., Kendall D.A., Bennett A.J., O'Sullivan S.E. Rimonabant in obese patients with type 2 diabetes. Lancet 2007, 369:555.
55. Rieder S.A., Chauhan A., Singh U., Nagarkatti M., Nagarkatti P.. 2009. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology. [Epub ahead of print].
56. Rockwell C.E., Kaminski N.E. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J. Pharmacol. Exp. Ther. 2004, 311:683-690.
57. Rockwell C.E., Snider N.T., Thompson J.T., Vanden Heuvel J.P., Kaminski N.E. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 2006, 70:101-111.
58. Ross R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 2009, 30:156-163.
59. Rubino T., Forlani G., Vigano D., Zippel R., Parolaro D. Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects. J. Neurochem. 2005, 93:984-991.
60. Salam N.K., Huang T.H.-W., Kota B.P., Kim M.S., Li Y., Hibbs D.E. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem. Biol. Drug Des. 2008, 71:57-70.
61. Schupp M., Curtin J.C., Kim R.J., Billin A.N., Lazar M.A. A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-γ activity. Mol. Pharmacol. 2007, 71:1251-1257.
62. Seimandi M., Lemaire G., Pillon A., Perrin A., Carlavan I., Voegel J.J. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal. Biochem. 2005, 344:8-15.
63. Shie F.S., Nivison M., Hsu P.C., Montine T.J. Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma. Curr. Med. Chem. 2009, 16:643-651.
64. Stella N. Endocannabinoid signaling in microglial cells. Neuropharmacology 2009, 56(Suppl. 1):244-253.
65. Stienstra R., Duval C., Müller M., Kersten S. PPARs, obesity, and inflammation. PPAR Res. 2007, 2007:95974.
66. Sun Y., Alexander S.P., Kendall D.A., Bennett A.J. Cannabinoids and PPARalpha signalling. Biochem. Soc. Trans. 2006, 34:1095-1097.
67. Upham B.L., Rummel A.M., Carbone J.M., Trosko J.E., Ouyang Y., Crawford R.B. Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. Int. J. Cancer 2003, 104:12-18.
68. Vanden Berghe W., Vermeulen L., Delerive P., De Bosscher K., Staels B., Haegeman G. A paradigm for gene regulation: inflammation, NF-κB and PPAR. Adv. Exp. Med. Biol. 2003, 544:181-196.
69. Waksman Y., Olson J.M., Carlisle S.J., Cabral G.A. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther. 1999, 288:1357-1366.
70. Woodward D.F., Liang Y., Krauss A.H. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br. J. Pharmacol. 2008, 153:410-419.
71. Yan Z.C., Liu D.Y., Zhang L.L., Shen C.Y., Ma Q.L., Cao T.B. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem. Biophys. Res. Commun. 2007, 354:427-433.
72. Yano M., Matsumura T., Senokuchi T., Ishii N., Murata Y., Taketa K. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ. Res. 2007, 100:1442-1451.
73. Zurier R.B., Sun Y.P., George K.L., Stebulis J.A., Rossetti R.G., Skulas A., Judge E., Serhan C.N. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB J. 2009, 2:1503-1509.